<DOC>
	<DOC>NCT02253186</DOC>
	<brief_summary>The objective of the study is to assess the effect of a new Armsleeve, worn during the night during maintenance phase of upper limb lymphoedema treatment in combination with Day-time usual lymphology hosiery.</brief_summary>
	<brief_title>Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema</brief_title>
	<detailed_description />
	<mesh_term>Lymphedema</mesh_term>
	<criteria>Unilateral secondary upper limb lymphoedema of stage II or III, following breast cancer Patients hospitalized for an intensive phase of decongestive lymphoedema therapy (DLT) for whom a decrease of lymphoedema volume has been achieved during hospitalization Lymphoedema with evident pitting sign (assessed as ++ or +++) Requiring compression therapy for, at least, the next 3 months. Affected arm that fits with one of the 6 standard sizes of the AutoAdjustable MOBIDERMÂ® armsleeve provided. Signed informed consent prior to any studymandated procedure. Not under any administrative or legal supervision. Covered by a health insurance system Stage I lymphoedema Active cellulitis Lymphoedema associated with active cancer needing acute chemotherapy Motor and sensitive neurological deficiency Postoperative oedema (i.e acute oedema following breast cancerrelated surgery) Patient participating in any other clinical study Unlikely to be followed up to 3 months with clinical assessment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>